secwatch.observer — SEC 8-K summary
======================================

Issuer:     COLLEGIUM PHARMACEUTICAL, INC (COLL)
CIK:        0001267565
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001558370-24-011583
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Collegium Q2 revenue up 7% to $145.3M; adjusted EPS $1.62; Ironshore acquisition on track
--------------------------------------------------------------------------------

- Net revenue $145.3M (+7% YoY); Belbuca record $52.2M (+21% YoY); GAAP net income $19.6M (+51% YoY).
- Non-GAAP adjusted net income $64.0M, adjusted EPS $1.62; Adjusted EBITDA $96.0M (+12% YoY).
- Acquiring Ironshore Therapeutics for $525M cash + up to $25M milestone; expected close Q3'24; funded by new $646M term loan.
- Reaffirmed FY2024 guidance: Product Revenue $580-595M, Adjusted EBITDA $380-395M.
- Pediatric exclusivity for Nucynta franchise extended to Jan 2027 (Nucynta) and Dec 2025 (Nucynta ER).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1267565/000155837024011583/0001558370-24-011583-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1267565/000155837024011583/coll-20240808x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-011583

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer